{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T04:16:26Z","timestamp":1782015386844,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Reproductive Immunology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jri.2021.103315","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T13:15:21Z","timestamp":1617023721000},"page":"103315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Risk factors for pregnancy morbidity in women with antiphospholipid syndrome"],"prefix":"10.1016","volume":"145","author":[{"given":"Jingjing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jri.2021.103315_bib0005","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00404-011-2055-y","article-title":"Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipd antibody syndrome","volume":"285","author":"Alalaf","year":"2012","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.jri.2021.103315_bib0010","doi-asserted-by":"crossref","first-page":"17104","DOI":"10.1038\/nrdp.2017.104","volume":"4","author":"Antiphospholipid syndrome","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.jri.2021.103315_bib0015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2013-08-522623","article-title":"Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study","volume":"123","author":"Bouvier","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jri.2021.103315_bib0020","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1182\/blood-2011-02-339234","article-title":"First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss","volume":"117","author":"Bramham","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jri.2021.103315_bib0025","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1034\/j.1600-0897.2001.d01-13.x","article-title":"Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis","volume":"46","author":"Carmona","year":"2001","journal-title":"Am. J. Reprod. Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.jri.2021.103315_bib0030","article-title":"Antiphospholipid syndrome","volume":"151","author":"Cervera","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jri.2021.103315_bib0035","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jri.2021.103315_bib0040","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jri.2021.103315_bib0045","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/art.11304","article-title":"Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group","volume":"48","author":"Costedoat-Chalumeau","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jri.2021.103315_bib0050","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/0961203312444172","article-title":"Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome","volume":"21","author":"De Carolis","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.jri.2021.103315_bib0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jri.2017.08.001","article-title":"Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome: a multicenter study","volume":"122","author":"Deguchi","year":"2017","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.jri.2021.103315_bib0060","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00006250-200212000-00032","article-title":"Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment","volume":"100","author":"Farquharson","year":"2002","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jri.2021.103315_bib0065","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.autrev.2011.10.006","article-title":"Obstetric antiphospholipid syndrome","volume":"11","author":"Galarza-Maldonado","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jri.2021.103315_bib0070","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bcp.12872","article-title":"Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis","volume":"81","author":"Kaplan","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jri.2021.103315_bib0075","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0961203317692432","article-title":"Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile","volume":"26","author":"Latino","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.jri.2021.103315_bib0080","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13219","article-title":"Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome: a systematic review and network meta-analysis","volume":"83","author":"Liu","year":"2020","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.jri.2021.103315_bib0085","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.autrev.2017.05.006","article-title":"Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a European multicenter retrospective study","volume":"16","author":"Mekinian","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jri.2021.103315_bib0090","first-page":"598","article-title":"[Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL]","volume":"46","author":"Mekinian","year":"2018","journal-title":"Gynecol. Obstet. Fertil. Senol."},{"key":"10.1016\/j.jri.2021.103315_bib0095","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jri.2021.103315_bib0100","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1067\/mob.2000.106754","article-title":"Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial","volume":"183","author":"Pattison","year":"2000","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jri.2021.103315_bib0105","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.jri.2021.103315_bib0110","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/rheumatology\/kes225","article-title":"Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?","volume":"51","author":"Reggia","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jri.2021.103315_bib0115","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/rheumatology\/ker139","article-title":"Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study","volume":"50","author":"Ruffatti","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jri.2021.103315_bib0120","article-title":"Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study","volume":"216","author":"Saccone","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jri.2021.103315_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2019.101463","article-title":"Antiphospholipid syndrome","volume":"34","author":"Sammaritano","year":"2020","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"Suppl 1","key":"10.1016\/j.jri.2021.103315_bib0130","article-title":"Managing antiphospholipid syndrome in pregnancy","volume":"181","author":"Schreiber","year":"2019","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jri.2021.103315_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.09.078","article-title":"The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies","volume":"214","author":"Sciascia","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jri.2021.103315_bib0140","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1600-0412.2011.01236.x","article-title":"High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome","volume":"90","author":"Simchen","year":"2011","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.jri.2021.103315_bib0145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/0366-6999.198934","article-title":"antiphospholipid antibody titers and clinical outcomes in patients with recurrent miscarriage and antiphospholipid antibody syndrome: a prospective study","volume":"130","author":"Song","year":"2017","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.jri.2021.103315_bib0150","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1701-2163(16)30644-2","article-title":"Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin","volume":"26","author":"Stephenson","year":"2004","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"10.1016\/j.jri.2021.103315_bib0155","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1067\/mob.2003.14","article-title":"Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy","volume":"188","author":"Stone","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jri.2021.103315_bib0160","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/s-0028-1082270","article-title":"Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment","volume":"34","author":"Tincani","year":"2008","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.jri.2021.103315_bib0165","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4103\/0366-6999.207471","article-title":"Efficacy of different treatment regimens for antiphospholipid syndrome-related recurrent spontaneous abortion","volume":"130","author":"Ye","year":"2017","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.jri.2021.103315_bib0170","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1177\/0961203318787032","article-title":"Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome","volume":"27","author":"Yelnik","year":"2018","journal-title":"Lupus"}],"container-title":["Journal of Reproductive Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165037821000450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165037821000450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:30:50Z","timestamp":1759033850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165037821000450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":34,"alternative-id":["S0165037821000450"],"URL":"https:\/\/doi.org\/10.1016\/j.jri.2021.103315","relation":{},"ISSN":["0165-0378"],"issn-type":[{"value":"0165-0378","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for pregnancy morbidity in women with antiphospholipid syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Reproductive Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jri.2021.103315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103315"}}